Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 441

1.

FGFR3 down-regulation is involved in BCG-induced bladder tumor growth inhibition.

Langle YV, Belgorosky D, Prack Mc Cormick B, Sahores A, Góngora A, Baldi A, Lanari C, Lamb C, Eiján AM.

J Urol. 2015 Jul 2. pii: S0022-5347(15)04308-6. doi: 10.1016/j.juro.2015.06.093. [Epub ahead of print]

PMID:
26144336
2.

A novel mutation Ser344Cys in FGFR3 causes achondroplasia with severe platyspondyly.

Takagi M, Kouwaki M, Kawase K, Shinohara H, Hasegawa Y, Yamada T, Fujiwara I, Sawai H, Nishimura G, Hasegawa T.

Am J Med Genet A. 2015 Jun 30. doi: 10.1002/ajmg.a.37231. [Epub ahead of print] No abstract available.

PMID:
26126848
3.

FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling.

Zhou S, Xie Y, Tang J, Huang J, Huang Q, Xu W, Wang Z, Luo F, Wang Q, Chen H, Du X, Shen Y, Chen D, Chen L.

PLoS Genet. 2015 Jun 19;11(6):e1005214. doi: 10.1371/journal.pgen.1005214. eCollection 2015 Jun.

4.

Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.

Zhang B, Dong S, Zhu R, Hu C, Hou J, Li Y, Zhao Q, Shao X, Bu Q, Li H, Wu Y, Cen X, Zhao Y.

Oncotarget. 2015 Jun 2. [Epub ahead of print]

5.

FGFR3 biology and skeletal disease.

Narayana J, Horton WA.

Connect Tissue Res. 2015 Jul 29:1-7. [Epub ahead of print]

PMID:
26075305
6.

Overexpression of miR-100 inhibits growth of osteosarcoma through FGFR3.

Bi Y, Jing Y, Cao Y.

Tumour Biol. 2015 May 29. [Epub ahead of print]

PMID:
26018508
7.

Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.

Hosen I, Rachakonda PS, Heidenreich B, de Verdier PJ, Ryk C, Steineck G, Hemminki K, Kumar R.

Int J Cancer. 2015 Oct 1;137(7):1621-9. doi: 10.1002/ijc.29526. Epub 2015 Apr 7.

PMID:
25809917
8.

Familial hypochondroplasia and acanthosis nigricans with FGFR3 K650T mutation.

Cossiez Cacard MA, Coulombe J, Bernard P, Kaci N, Bressieux JM, Souchon PF, Motte J, Legeai-Mallet L, Hadj-Rabia S, Eschard C.

J Eur Acad Dermatol Venereol. 2015 Mar 24. doi: 10.1111/jdv.13061. [Epub ahead of print] No abstract available.

PMID:
25809207
9.

Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3).

Li Y, Delamar M, Busca P, Prestat G, Le Corre L, Legeai-Mallet L, Hu R, Zhang R, Barbault F.

J Comput Aided Mol Des. 2015 Jul;29(7):619-41. doi: 10.1007/s10822-015-9841-8. Epub 2015 Mar 26.

PMID:
25808135
10.
11.

A novel variant of FGFR3 causes proportionate short stature.

Kant SG, Cervenkova I, Balek L, Trantirek L, Santen GW, de Vries MC, van Duyvenvoorde HA, van der Wielen MJ, Verkerk AJ, Uitterlinden AG, Hannema SE, Wit JM, Oostdijk W, Krejci P, Losekoot M.

Eur J Endocrinol. 2015 Jun;172(6):763-70. doi: 10.1530/EJE-14-0945. Epub 2015 Mar 16.

PMID:
25777271
12.

Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.

Palma N, Morris JC, Ali SM, Ross JS, Pal SK.

Eur Urol. 2015 Jul;68(1):168-70. doi: 10.1016/j.eururo.2015.02.023. Epub 2015 Mar 9. No abstract available.

PMID:
25766722
13.

FGFR3 unliganded dimer stabilization by the juxtamembrane domain.

Sarabipour S, Hristova K.

J Mol Biol. 2015 Apr 24;427(8):1705-14. doi: 10.1016/j.jmb.2015.02.013. Epub 2015 Feb 15.

PMID:
25688803
14.

TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.

Wang K, Liu T, Liu C, Meng Y, Yuan X, Liu L, Ge N, Liu J, Wang C, Ren H, Yan K, Hu S, Xu Z, Fan Y, Xu D.

Oncologist. 2015 Mar;20(3):263-9. doi: 10.1634/theoncologist.2014-0391. Epub 2015 Feb 5.

PMID:
25657201
15.

Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation.

McAuliffe S, Brown R, Catalano A, Ho PJ, Nassif N, Woodland N, Hart D, Weatherburn C, Yang S, Suen H, Paul C, Joshua D, Gibson J.

Leuk Lymphoma. 2015 Feb 17:1-3. [Epub ahead of print] No abstract available.

PMID:
25651422
16.

FGFR3 mutation frequency in 324 cases from the International Skeletal Dysplasia Registry.

Xue Y, Sun A, Mekikian PB, Martin J, Rimoin DL, Lachman RS, Wilcox WR.

Mol Genet Genomic Med. 2014 Nov;2(6):497-503. doi: 10.1002/mgg3.96. Epub 2014 Aug 5.

17.

Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization.

Del Piccolo N, Placone J, Hristova K.

Biophys J. 2015 Jan 20;108(2):272-8. doi: 10.1016/j.bpj.2014.11.3460.

PMID:
25606676
18.

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.

Nakanishi Y, Akiyama N, Tsukaguchi T, Fujii T, Satoh Y, Ishii N, Aoki M.

Mol Cancer Ther. 2015 Mar;14(3):704-12. doi: 10.1158/1535-7163.MCT-14-0927-T. Epub 2015 Jan 14.

PMID:
25589496
19.

FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.

Smal MP, Rolevich AI, Polyakov SL, Krasny SA, Goncharova RI.

Exp Oncol. 2014 Dec;36(4):246-51.

PMID:
25537218
20.

Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.

Yuan L, Liu ZH, Lin ZR, Xu LH, Zhong Q, Zeng MS.

Cancer Biol Ther. 2014;15(12):1613-21. doi: 10.4161/15384047.2014.961874.

PMID:
25535896
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk